MCID: CHL028
MIFTS: 58

Childhood Type Dermatomyositis

Categories: Blood diseases, Bone diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 12 15
Juvenile Dermatomyositis 12 73 20 58 17 70 32
Juvenile Dm 20 58
Dermatomyositis, Childhood Type 70
Childhood Dermatomyositis 12

Characteristics:

Orphanet epidemiological data:

58
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Childhood Type Dermatomyositis

GARD : 20 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema, muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures. Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected. About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to interstitial lung disease and skin disease. An important gene associated with Childhood Type Dermatomyositis is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Measles. The drugs Abatacept and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and bone, and related phenotypes are muscle weakness and fatigue

Wikipedia : 73 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.2 TRIM21 TNF MORC3 IFIH1
2 skin disease 30.6 TNF MX1 IFNA1 ICOSLG CD4 CCR6
3 calcinosis 30.5 TNF PIK3C2A HLA-DQA1
4 autoimmune vasculitis 30.3 TNF CD4 CCR6
5 polymyositis 30.3 PIK3C2A HARS1 EXOSC10
6 respiratory failure 30.3 TNF PIK3C2A CD4 CCR6
7 t cell deficiency 30.1 ICOSLG CD4 CCR6
8 autoimmune gastritis 30.1 TNF CD4 CCR6
9 cellulitis 30.1 TNF CD4 CCR6
10 mixed connective tissue disease 30.1 TNF SNRNP70 HLA-DQA1
11 lupus erythematosus 30.0 TRIM21 TNF SNRNP70 MX1 IFIH1 HLA-DQA1
12 acute cystitis 30.0 TNF CD4 CCR6
13 herpes zoster 30.0 TNF IFNA1 ICOSLG CD4 CCR6
14 panniculitis 30.0 TNF CD4 CCR6
15 central nervous system disease 30.0 TNF MIR10A ICOSLG CCR6
16 mumps 29.9 TNF MX1 IFNA1
17 severe acute respiratory syndrome 29.9 TNF MX1 IFNA1 IFIH1
18 chickenpox 29.8 TNF IFNA1 ICOSLG CD4 CCR6
19 muscular disease 29.8 TRIM33 TNF PIK3C2A MORC3 MIR10A IFIH1
20 nervous system disease 29.8 TNF MIR10A ICOSLG CD4 CCR6
21 disease by infectious agent 29.8 TNF IFNA1 ICOSLG CD4 CCR6
22 dermatitis, atopic 29.8 TNF ICOSLG CD4 CCR6
23 celiac disease 1 29.7 TNF IFIH1 ICOSLG HLA-DQA1 CD4 CCR6
24 deficiency anemia 29.6 TNF IFNA1 ICOSLG CD4 CCR6
25 immune deficiency disease 29.6 TNF IFNA1 ICOSLG CXCR5 CD4 CCR6
26 influenza 29.4 TNF MX1 MORC3 ISG15 IFNA1 IFIH1
27 bacterial infectious disease 29.4 TNF MX1 ISG15 ICOSLG CD4 CCR6
28 systemic scleroderma 29.4 TRIM21 TNF SNRNP70 ICOSLG EXOSC10 CD4
29 autoimmune disease 29.3 TRIM21 TNF IFNA1 IFIH1 ICOSLG HLA-DQA1
30 connective tissue disease 29.2 TNF SNRNP70 MIR10A ICOSLG HLA-DQA1 CD4
31 exanthem 29.2 TRIM21 TNF PIK3C2A IFNA1 IFIH1 ICOSLG
32 adult dermatomyositis 29.2 TRIM33 TRIM24 TRIM21 TNF MORC3 ISG15
33 systemic lupus erythematosus 28.9 TRIM21 TNF SNRNP70 MX1 ISG15 IFNA1
34 myositis 28.5 TRIM33 TRIM21 TNF PIK3C2A NT5C1A IFNA1
35 dermatomyositis 10.7
36 lung disease 10.6
37 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.5
38 dysphagia 10.4
39 myelitis 10.4 TNF ICOSLG CCR6
40 mulchandani-bhoj-conlin syndrome 10.4 ICOSLG CXCR5 CCR6
41 subacute cutaneous lupus erythematosus 10.4 TRIM21 TNF
42 immunodeficiency 35 10.4 IFNA1 ICOSLG CCR6
43 igg4-related disease 10.3 IFNA1 ICOSLG CCR6
44 transverse myelitis 10.3 TNF ICOSLG CCR6
45 facial hemiatrophy 10.3 SNRNP70 EXOSC10
46 posterior uveitis 10.3 TNF ICOSLG CCR6
47 orbital plasma cell granuloma 10.3 TRIM33 PIK3C2A MORC3
48 chronic orbital inflammation 10.3 TRIM33 PIK3C2A MORC3
49 monoclonal gammopathy of uncertain significance 10.3 TNF ICOSLG CCR6
50 granulomatous myositis 10.3 TRIM21 PIK3C2A

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

58 31 (show all 46)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 dry skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000958
4 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
5 elevated serum creatine kinase 58 31 hallmark (90%) Very frequent (99-80%) HP:0003236
6 palpebral edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0100540
7 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
8 mucosal telangiectasiae 58 31 hallmark (90%) Very frequent (99-80%) HP:0100579
9 telangiectasia of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0100585
10 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
11 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
12 elevated c-reactive protein level 58 31 hallmark (90%) Very frequent (99-80%) HP:0011227
13 myositis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100614
14 elevated erythrocyte sedimentation rate 58 31 hallmark (90%) Very frequent (99-80%) HP:0003565
15 calcinosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0003761
16 constipation 58 31 frequent (33%) Frequent (79-30%) HP:0002019
17 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
18 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
19 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
20 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
21 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
22 vasculitis 58 31 frequent (33%) Frequent (79-30%) HP:0002633
23 cutaneous photosensitivity 58 31 frequent (33%) Frequent (79-30%) HP:0000992
24 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
25 restrictive ventilatory defect 58 31 frequent (33%) Frequent (79-30%) HP:0002091
26 poikiloderma 58 31 frequent (33%) Frequent (79-30%) HP:0001029
27 muscle spasm 58 31 frequent (33%) Frequent (79-30%) HP:0003394
28 hypotonia 31 frequent (33%) HP:0001252
29 dysarthria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001260
30 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
31 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
32 emg abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0003457
33 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
34 angina pectoris 58 31 occasional (7.5%) Occasional (29-5%) HP:0001681
35 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
36 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
37 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
38 bundle branch block 58 31 occasional (7.5%) Occasional (29-5%) HP:0011710
39 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
40 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
41 hoarse voice 58 31 occasional (7.5%) Occasional (29-5%) HP:0001609
42 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
43 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
44 limitation of joint mobility 58 31 occasional (7.5%) Occasional (29-5%) HP:0001376
45 cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001638
46 muscular hypotonia 58 Frequent (79-30%)

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2 Antirheumatic Agents Phase 4
3 Immunosuppressive Agents Phase 4
4 Immunologic Factors Phase 4
5
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
6
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
7
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
8
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
9
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
10
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
11
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
12
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
13
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
14
leucovorin Approved Phase 3 58-05-9 6006
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
17 glucocorticoids Phase 2, Phase 3
18 Vitamin B9 Phase 3
19 Methylprednisolone Acetate Phase 3
20 Folate Phase 3
21 Cyclosporins Phase 3
22 Antidotes Phase 2
23 Pharmaceutical Solutions Phase 2
24 Chelating Agents Phase 2
25 Protective Agents Phase 2
26 Antioxidants Phase 2
27 sodium thiosulfate Phase 2
28 Anti-Infective Agents Phase 2
29 Anti-Bacterial Agents Phase 2
30 Antitubercular Agents Phase 2
31 Antiemetics Phase 2
32 Hormones Phase 2
33 Gastrointestinal Agents Phase 2
34 Neuroprotective Agents Phase 2
35 Hormone Antagonists Phase 2
36 Anti-Inflammatory Agents Phase 2
37 Antineoplastic Agents, Hormonal Phase 2
38
Creatine Approved, Investigational, Nutraceutical 57-00-1 586

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Completed NCT02594735 Phase 4 Abatacept
2 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
3 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Completed NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
4 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
5 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
6 Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015 Unknown status NCT03432455
7 Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis Unknown status NCT01217320
8 Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace Unknown status NCT03433638
9 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005
10 Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis Recruiting NCT00059748
11 Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Genetic Tests for Childhood Type Dermatomyositis

Anatomical Context for Childhood Type Dermatomyositis

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

40
Skeletal Muscle, Skin, Bone, Lung, Endothelial, Eye, T Cells

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 1185)
# Title Authors PMID Year
1
Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. 61
32841547 2021
2
The spectrum of idiopathic inflammatory myopathies in South Africa. 61
32212001 2021
3
Juvenile dermatomyositis: a case of delayed recognition with unusual complication of nephrocalcinosis. 61
33795282 2021
4
Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain. 61
32989504 2021
5
Hypopigmentation in the Medial Angle of Eyes in a Young Boy With Juvenile Dermatomyositis. 61
31977652 2021
6
Scalp calcinosis in juvenile dermatomyositis. 61
33677594 2021
7
Juvenile dermatomyositis with gingival vasculopathy. 61
33660083 2021
8
Autoantibody Profile of Children with Juvenile Dermatomyositis. 61
33694062 2021
9
Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report. 61
33740993 2021
10
Myositis-specific autoantibodies as relevant adjusting variables in myositis research. 61
33645884 2021
11
Response to: "Myositis-specific autoantibodies as relevant adjusting variables in myositis research" by Pinal Fernandez et al. Correspondence on "From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies". 61
33645888 2021
12
Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis. 61
33686540 2021
13
Kawasaki disease malingering as juvenile dermatomyositis: case-based review : Myositis in Kawasaki disease. 61
33682025 2021
14
Outcome Scores in Pediatric Rheumatology. 61
33683471 2021
15
Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. 61
33360233 2021
16
Population pharmacokinetics of mycophenolic acid in pediatric patients with juvenile dermatomyositis and optimization of limited sampling strategy. 61
32903096 2021
17
Treatment of Calcinosis in Juvenile Dermatomyositis. 61
33555459 2021
18
Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. 61
32810267 2021
19
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. 61
33576769 2021
20
Tibia stress injury and the imaging appearance of stress fracture in juvenile dermatomyositis: six patients' experiences. 61
33596941 2021
21
Resolution of calcinosis using bisphosphonates in overlap syndrome - a case report. 61
33632332 2021
22
Catch the thief by its marks: inverse Gottron papules, interstitial lung disease, anti MDA-5 antibody positivity in juvenile dermatomyositis. 61
32888028 2021
23
Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. 61
33528490 2021
24
Importance of immunohistochemical evaluation of developmentally regulated myosin heavy chains in human muscle biopsies. 61
33685841 2021
25
Engaging patients and parents to improve mental health intervention for youth with rheumatological disease. 61
33622346 2021
26
[Application and safety of hydroxychloroquine in chronic disease among children]. 61
33548956 2021
27
Anti-cN-1A autoantibodies are absent in juvenile dermatomyositis. 61
33497020 2021
28
Readability of online patient education materials for juvenile dermatomyositis. 61
33452694 2021
29
Inflammatory milieu of muscle biopsies in juvenile dermatomyositis. 61
33106894 2021
30
Atypical juvenile dermatomyositis complicated by systemic capillary leak syndrome: case report and review of the literature. 61
32772096 2021
31
Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study. 61
32238513 2021
32
Correlation of a Modified Disease Activity Score (DAS) with the Validated Original DAS in Patients with Juvenile Dermatomyositis. 61
32173660 2021
33
Patient and parent perspectives on transition from paediatric to adult healthcare in rheumatic diseases: an interview study. 61
33397662 2021
34
The Vasculopathy of Juvenile Dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness. 61
33393715 2021
35
Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients: Analysis From a Multicentric Cohort in Spain. 61
33492027 2021
36
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. 61
33019894 2021
37
Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. 61
33407621 2021
38
Anti-MDA5 antibody-positive juvenile dermatomyositis overlap with neuropsychiatric systemic lupus erythematosus: a case report. 61
33253101 2021
39
Biologics in refractory idiopathic inflammatory myositis (IIM): What experience in juvenile vs adult myositis tells us about the use of biologics in pediatric IIM. 61
33499694 2021
40
Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature. 61
33407602 2021
41
Clinical characteristics and management of clinically amyopathic juvenile dermatomyositis across four academic centers. 61
33438772 2021
42
From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies. 61
33314705 2020
43
Studies of 96 children with Juvenile Dermatomyositis: P155/140, is associated with loss of nailfold capillaries, but not generalized lipodystrophy. 61
33290639 2020
44
[The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis]. 61
33256317 2020
45
Rituximab for Inflammatory Myopathies in a Colombian Cohort. 61
33337818 2020
46
What is in the Myopathy Literature? 61
33214392 2020
47
Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis. 61
33359787 2020
48
Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients. 61
33337999 2020
49
Why is a paediatric respiratory specialist integral to the paediatric rheumatology clinic? 61
33447294 2020
50
A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. 61
32754736 2020

Variations for Childhood Type Dermatomyositis

Expression for Childhood Type Dermatomyositis

LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1 Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine/uridine monophosphate kinase 2 Skeletal Muscle + 4.61 0.000
7 IFI44L interferon induced protein 44 like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon alpha inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 C-X-C motif chemokine ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4 Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin heavy chain 3 Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon alpha inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly(ADP-ribose) polymerase family member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon gamma inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1 Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome 20S subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex E3 ubiquitin ligase 3L Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1 Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 TNF superfamily member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly(ADP-ribose) polymerase family member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.

Pathways for Childhood Type Dermatomyositis

Pathways related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.02 TRIM21 TNF MX1 ISG15 IFNA1 HLA-DQA1
2
Show member pathways
12.44 TNF MX1 ISG15 IFNA1 IFIH1 HLA-DQA1
3
Show member pathways
12.21 TRIM21 MX1 ISG15 IFNA1 HLA-DQA1
4
Show member pathways
12.09 PIK3C2A ICOSLG HLA-DQA1 CD4
5
Show member pathways
11.91 TNF IFNA1 ICOSLG HLA-DQA1 HARS1 CXCR5
6 11.6 TNF HLA-DQA1 CD4
7 11.36 TNF CXCR5 CD4 CCR6
8 11.08 TNF ICOSLG CXCR5 CCR6

GO Terms for Childhood Type Dermatomyositis

Cellular components related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 TNF ICOSLG CXCR5 CD4 CCR6

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 MX1 ISG15 IFIH1 ICOSLG HLA-DQA1 CD4
2 immune response GO:0006955 9.83 TNF HLA-DQA1 CXCR5 CD4 CCR6
3 defense response to virus GO:0051607 9.56 MX1 ISG15 IFNA1 IFIH1
4 type I interferon signaling pathway GO:0060337 9.5 MX1 ISG15 IFNA1
5 positive regulation of viral entry into host cell GO:0046598 9.46 TRIM21 CD4
6 response to type I interferon GO:0034340 9.37 MX1 ISG15
7 humoral immune response GO:0006959 9.33 TNF IFNA1 CCR6
8 defense response GO:0006952 9.26 TNF MX1 IFNA1 ICOSLG
9 negative regulation of viral genome replication GO:0045071 8.8 TNF MX1 ISG15

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.1 TRIM33 TRIM24 TRIM21 MORC3 IFIH1 CD4

Sources for Childhood Type Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....